Literature on the use of nutritional supplements (NS) in tennis players is scarce. The objective of the present study was to evaluate NS consumption in a group of men's tennis players who participated in the 2016 Andalusian team championship. A total of 70 questionnaires from 7 different clubs were registered. The questionnaire was previously designed and evaluated through piloting in which the validity of the content, its application, its structure and its presentation were observed. The results showed that 100% of the sample group was in favor of NS consumption within the law, 88.6% claimed to have consumed them at some time and 61.4% presently consume them. The NS most consumed by study participants were sports drinks (69.35%), energy bars (29%), a vitamin complex (19.35%), protein (serum) (17.74%) and creatine (14.51%). A high percentage of NS consumers thought that they had obtained positive results from NS consumption. The percentages and the findings regarding NS consumption in the present study were similar to the contributions made by other studies which evaluated supplementation in athletes, although with some subtle differences.

Intermediate CAG expansions in the gene ataxin-2 (ATXN2) are a known risk factor for ALS, but little is known about their role in FTD risk. Moreover, their contribution to the risk and phenotype of patients might vary in populations with different genetic background. The aim of this study was to assess the relationship of intermediate CAG expansions in ATXN2 with the risk and phenotype of ALS and FTD in the Spanish population. Repeat-Primed PCR was performed in 620 ALS and 137 FTD patients in three referral centers of Spain to determine the exact number of CAG repeats. In our cohort, ≥27 CAG repeats in ATXN2 was associated with a higher risk of developing ALS (odds ratio [OR] = 2.666 [1.471-4.882]; p = 0.0013), but not FTD (odds ratio [OR] = 1.446 [0.558-3.574]; p = 0.44). Moreover, ALS patients with ≥27 CAG repeats in ATXN2 showed shorter survival rate compared to those with <27 repeats (hazard ratio [HR] 1.74 [1.18, 2.56], p = 0.005), more frequent limb onset (odds ratio [OR] = 2.34 [1.093-4.936]; p = 0.028), as well as family history of ALS (odds ratio [OR] = 2.538 [1.375-4.634]; p = 0.002). Intermediate CAG expansions of ≥27 repeats in ATXN2 are associated with ALS risk, but not with FTD, in the Spanish population. ALS patients carrying an intermediate expansion in ATXN2 show more frequent limb onset, but worse prognosis than those without expansions. In patients carrying C9orf72 expansions, the intermediate ATXN2 expansion might increase the penetrance and modify the phenotype.